Editing Samuel D. Waksal (section)

==Kadmon Pharmaceuticals==
In 2009, upon his release from prison Waksal began fundraising and launched the company [[Kadmon Pharmaceuticals]] in New York City.<ref>{{cite web|url=http://www.fiercebiotech.com/biotech/waksal-s-latest-biotech-play-reportedly-trying-to-go-public-after-two-misfires|title=Waksal's Latest Biotech Play is Reportedly Trying to go Public After Two Misfires|publisher=FierceBiotech|first=Damian |last=Garde |date=February 2, 2016 |access-date=September 5, 2016}}</ref><ref>{{cite news|url=https://www.nytimes.com/2010/11/01/business/01waksal.html|title=ImClone Ex-Chief Embarks on New Biotech Venture|newspaper=The New York Times|first=Andrew |last=Pollack |date=October 31, 2010|access-date=September 5, 2016}}</ref> Waksal was forced to step down from the CEO position in 2014 as the company planned an [[initial public offering|IPO]], because his sentence also ruled that he was banned from serving as an officer or director to any public company for life. With Waksal leaving the role, his brother Harlan began serving as CEO.<ref>{{cite news|url=https://dealbook.nytimes.com/2014/09/25/sam-waksals-new-biotech-venture-tests-investor-forgiveness/|title=Sam Waksal's New Biotech Venture Tests Investor Forgiveness|newspaper=The New York Times|first=Robert|last=Cyran|date=September 25, 2014 |access-date=September 5, 2016}}</ref> Waksal remained with the company and transitioned into the role of Chief of Innovation.<ref>{{cite web|url=https://www.cnbc.com/2016/02/02/waksals-kadmon-said-to-plan-ipo-without-waksal.html|title=Waksal's Kadmon Said to Plan IPO, Without Waksal|publisher=CNBC|first=Meg |last=Tirrell|date=February 2, 2016 |access-date=September 5, 2016}}</ref> In February 2016, Waksal left the Kadmon Pharmaceuticals but remained a shareholder in the company. In June 2016, the company announced it had filed the paperwork to undergo an [[IPO]].<ref>{{cite web|url= http://www.xconomy.com/new-york/2016/06/13/kadmon-seeks-ipo-with-unusual-terms-that-benefit-waksal-debt-holders/#|title=Kadmon Seeks IPO With Unusual Terms That Benefit Waksal, Debt Holders|first=Alex |last=Lash|work=Xconomy |date=June 13, 2016 |access-date=September 5, 2016}}</ref><ref>{{cite web|url=http://www.fiercebiotech.com/sam-waksal-exited-kadmon-25m-severance-deal-ahead-ipo|title=Sam Waksal Exited Kadmon With $25M Severance Deal Ahead of IPO|publisher=FierceBiotech|first=John |last=Carroll |date=June 10, 2016 |access-date=September 5, 2016}}</ref><ref>{{cite web|url=http://fortune.com/2016/06/17/sam-waksal-theranos-scam/|title=Convicted Pharma Fraudster Waksal Calls Theranos a 'Scam'|publisher=Fortune|first=Sy |last=Mukherjee |date=June 17, 2016 |access-date=September 5, 2016}}</ref> In July 2016, the company raised $75 million in its IPO.<ref>{{cite news|url=https://www.wsj.com/articles/redemption-on-offer-as-disgraced-executive-sam-waksals-startup-readies-ipo-1469562708|title=Redemption on Offer As Disgraced Executive Sam Wakssal's Startup Launches IPO|newspaper=The Wall Street Journal|first=Gregory |last=Zuckerman|date=July 26, 2016|access-date=September 5, 2016}}</ref>